COMMUNIQUÉS West-GlobeNewswire

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

27/04/2025 - 18:05

Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer REDWOOD [...]

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

27/04/2025 - 20:00

Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ABP-102/CT-P72 HER2 [...]

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

27/04/2025 - 21:00

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]

Precede Biosciences Presents Data at AACR 2025 Demonstrating Ability to Resolve Gene Expression for Thousands of Tumor-Specific Genes from a Simple Blood Test

27/04/2025 - 21:00

Comprehensive epigenomic platform enables systematic and quantitative prediction of tumor gene expression from cell-free DNA Genes include key targets for next generation precision medicines, such as NECTIN4, B7H4, HER3 [...]

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

27/04/2025 - 16:35

STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the [...]

Mitolyn Reviews: DO NOT Spend A Dime Until You’ve Read This Report?

27/04/2025 - 17:05

The weight loss revolution : Mitolyn's Mitochondrial Mastery System Delivers Sustainable Fat Burning Together with Increased Energy Levels Albany, New York, April 27, 2025 (GLOBE NEWSWIRE) -- Various weight loss [...]

Best Male Enhancement Pills & Libido Booster For Men: (Penis Enlargement Pills) Over The Counter Best ED Pills Non Prescription – By Performer 8

27/04/2025 - 13:32

More than 50% of men now face erectile dysfunction after the age of 40. In a few cases, men in their 20s and 30s face a similar situation. You can find here the Best Male Enhancement Pills & Libido Booster for Men ( [...]

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

27/04/2025 - 15:00

Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025 CORAL GABLES, Fla., April 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a [...]

2025 (Spring) Pharmaceutical Machinery Exposition Concludes Successfully

27/04/2025 - 11:15

BEIJING, April 27, 2025 (GLOBE NEWSWIRE) -- On April 25, 2025, the 66th (Spring 2025) National Pharmaceutical Machinery Exposition & 2025 (Spring) China International Pharmaceutical Machinery Exposition (hereinafter [...]

Best Legal Steroids For Muscle Growth: Top Anabolic Steroids Alternatives For (Bulking & Bodybuilding) That Really Work – By Crazy Bulk

27/04/2025 - 01:29

After six months of research on the ingredients and thousands of feedback from real consumers, we can safely say that legal steroids are 100% legal and they do work for bulking and bodybuilding. New York City, April 26 [...]

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

26/04/2025 - 21:05

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one [...]

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

26/04/2025 - 22:10

- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients [...]

Three-Year Data of Zenflow’s Spring System Demonstrate Durability of Clinical Benefits for Patients Suffering from BPH

26/04/2025 - 23:36

Data Presented at the AUA Meeting Reflect Longest-Term Data among FIT Interventions SOUTH SAN FRANCISCO, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- Zenflow, Inc. announced today the results of long-term data [...]

Valneva fait un point sur la recommandation d’utilisation de son vaccin contre le chikungunya par les autorités françaises

26/04/2025 - 19:10

Saint Herblain (France), le 26 avril 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’autorité publique de santé en France, la Haute Autorité de [...]

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

26/04/2025 - 19:10

Saint Herblain (France), April 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France’s national public health agency, the Haute Autorité de Santé (HAS), has [...]

Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer

26/04/2025 - 19:50

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR 1 Results reinforce potential of TAR-200 to [...]

Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC

26/04/2025 - 20:00

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical [...]

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

26/04/2025 - 16:00

TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients TARA-002 demonstrates 76% complete response rate at any time and 43% 12-month [...]

Best Legal Steroids For Muscle Growth: Best Oral Steroids, Safest Steroids, Best Steroids for Muscle Gain, Best Steroid Cycle, Steroids best for muscle growth Anabolic Steroids vs Testosterone By CrazyBulk

26/04/2025 - 12:26

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- Benefits of Legal Steroids for Building Muscle Legal steroids are a safe and effective way to gain muscle and strength without the dangerous side effects of anabolic steroids [...]